Determining Losses in Jet Injection Subcutaneous Insulin Delivery: A Model-Based Approach
Authors' conclusion
Modeling shows needle-free SC jet injection of a nominal dose of insulin does not necessarily provide metabolic action equivalent to total dose, and this availability significantly varies between trials. By quantifying and accounting for variability of jet injection insulin doses, better glycemic management outcomes using SC jet injection may be achieved.
Study context
- Population
- Healthy adults receiving 2U subcutaneous (SC) insulin by needle-free jet injection
- Participants
- 7 healthy adults
- Outcome
- Expected proportion of active insulin present from a needle-free SC dose (insulin delivery loss)
Methodological detailsmodel-based, frequently sampled insulin-modified OGTT, Insulin, C-peptide and glucose assay data paired with a well-validated metabolic model; hepatic clearance modelled with third-order basis splines
- Model-based
- Frequently sampled insulin-modified OGTT
- Insulin, C-peptide and glucose assay data paired with a well-validated metabolic model; hepatic clearance modelled with third-order basis splines
Main finding
As reported in the abstract
Insulin delivery loss
Losses of the nominal 2U SC dose, up to
22%
Original publication
Determining Losses in Jet Injection Subcutaneous Insulin Delivery: A Model-Based Approach. J Diabetes Sci Technol. Published 26 March 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →